Clinical Trials Browser

NCT05554419 2026-03-19

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

184 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

60 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07388563 2026-03-18

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Phase 1 Not yet recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

VENP-A-QUI

MDS

VAH vs VA in Newly Diagnosed Elderly AML

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

MIVONU

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

GAVEL

VAG-3+7-G

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

M-HArbOr

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

SEVENAZA

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

AZA+Lus VS AZA Monotherapy in HR-MDS